Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Tolerability of Kangdaprevir in Healthy Adults
NCT03811678Phase 1Completed
- Sponsor
- Sunshine Lake Pharma
- Start
- Jan 2018
- Primary completion
- May 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of kangdaprevir in hepatitis C (HCV) (9 arms), sponsored by Sunshine Lake Pharma. Primary endpoints: Adverse events, Maximum Plasma Concentration and 6 more. Started Jan 2018; status: completed.
02
Drugs
kangdaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03811678.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03811678.